New therapies for treatment of rheumatoid arthritis

Lancet

Volumn 370, Issue 9602, 2007, Pages 1861-1874

  Smolen, Josef S ^a,b   Aletaha, Daniel ^a   Koeller, Marcus ^a   Weisman, Michael H ^c   Emery, Paul ^d  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Neurological Center Rosenhuegel   (Austria)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d CHAPEL ALLERTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ATLIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; NATALIZUMAB; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CELLULITIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DISEASE ACTIVITY; DIVERTICULITIS; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG TARGETING; DRUG WITHDRAWAL; DYSPNEA; HEADACHE; HUMAN; HYPERTENSION; HYPOTENSION; IMMUNOGLOBULIN BLOOD LEVEL; INFUSION REACTION; MONOTHERAPY; NEUTROPENIA; PATHOGENESIS; PNEUMONIA; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SEPSIS; SIDE EFFECT; STOMATITIS; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; URINARY TRACT INFECTION; URTICARIA; WHEEZING;

EID: 35648988128     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)60784-3     Document Type: Review

References (155)

1. Gabriel S. The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am 27 (2001) 269-281
2. Choi H., Hernan M., Seeger J., Robins J., and Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 359 (2002) 1173-1177
3. Pincus T., Brooks R., and Callahan L. Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures. Ann Intern Med 120 (1994) 26-34
4. Gregersen P., Silver J., and Winchester R. The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 30 (1987) 1205-1213
5. Mueller D., Jenkins M., and Schwartz R. Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol 7 (1989) 445-480
6. Frauwirth K., and Thompson C. Activation and inhibition of lymphocytes by costimulation. J Clin Invest 109 (2002) 295-299
7. Ehrenstein M., Evans J., Singh A., et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 200 (2004) 277-285
8. Shevach E. Regulatory/suppressor T cells in health and disease. Arthritis Rheum 50 (2004) 2721-2724
9. Tang Q., and Bluestone J. Regulatory T-cell physiology and application to treat autoimmunity. Immunol Rev 212 (2006) 217-237
10. Bombara M., Webb D., Conrad P., et al. Cell contact between T cells and synovial fibroblasts causes induction of adhesion molecules and cytokines. J Leukoc Biol 54 (1993) 399-406
11. Kong Y., Feige U., Sarosi I., et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402 (1999) 304-309
12. Steiner G., and Smolen J. Autoantibodies in rheumatoid arthritis. In: Firestein G., Panayi G., and Wollheim F. (Eds). Rheumatoid arthritis. 2nd edn. (2006), Oxford University Press, Oxford 194-198
13. Debets J., Van der Linden C., Dieteren I., Leeuwenberg J., and Buurman W. Fc-receptor cross-linking induces rapid secretion of tumor necrosis factor (cachectin) by human peripheral blood monocytes. J Immunol 141 (1988) 1197-1201
14. Rantapaa-Dahlqvist S. Diagnostic and prognostic significance of autoantibodies in early rheumatoid arthritis. Scand J Rheumatol 34 (2005) 83-96
15. Nell V., Machold K., Stamm T., et al. Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis 64 (2005) 1731-1736
16. Rodriguez-Pinto D. B cells as antigen presenting cells. Cell Immunol 238 (2005) 67-75
17. Thomas R., Thompson A., Martin E., and O'Sullivan B. Dendritic cells. In: Smolen J., and Lipsky P. (Eds). Targeted therapies in rheumatology (2003), Martin Dunitz, London 61-81
18. Panayi G. B cells: a fundamental role in the pathogenesis of rheumatoid arthritis?. Rheumatology (Oxford) 44 suppl 2 (2005) ii3-ii7
19. Firestein G. Invasive fibroblast-like synoviocytes in rheumatoid arthritis: passive responders or transformed aggressors?. Arthritis Rheum 39 (1996) 1781-1790
20. Lee Z., and Firestein G. Fibroblasts. In: Smolen J., and Lipsky P. (Eds). Targeted therapies in rheumatology (2003), Martin Dunitz, London 133-146
21. Pap T., Claus A., Ohtsu S., et al. Osteoclast-independent bone resorption by fibroblast-like cells. Arthritis Res Ther 5 (2003) R163-R173
22. Muller-Ladner U., Kriegsmann J., Franklin B., et al. Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice. Am J Pathol 149 (1996) 1607-1615
23. Gravallese E., Harada Y., Wang J., Gorn A., Thornhill T., and Goldring S. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol 152 (1998) 943-951
24. Redlich K., Hayer S., Ricci R., et al. Osteoclasts are essential for TNF-α-mediated joint destruction. J Clin Invest 110 (2002) 1419-1427
25. Firestein G., Alvaro-Gracia J., and Maki R. Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J Immunol 144 (1990) 3347-3353
26. Steiner G., Tohidast-Akrad M., Witzmann G., et al. Cytokine production by synovial T cells in rheumatoid arthritis. Rheumatology (Oxford) 38 (1999) 202-213
27. Chu C., Field M., Feldmann M., and Maini R. Localization of tumor-necrosis factor-alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum 34 (1991) 1125-1132
28. Feldmann M., Brennan F., Foxwell B., and Maini R. The role of TNF alpha and IL-1 in rheumatoid arthritis. Curr Dir Autoimmun 3 (2001) 188-199
29. Nishimoto N., Yoshizaki K., and Kishimoto T. Interleukin 6. In: Smolen J., and Lipsky P. (Eds). Targeted therapies in rheumatology (2003), Martin Dunitz, London 231-241
30. Gracie J., Forsey R., Chan W., et al. A proinflammatory role for IL-18 in rheumatoid arthritis. J Clin Invest 104 (1999) 1393-1401
31. McInnes I., Leung B., Sturrock R., Field M., and Liew F. Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-alpha production in rheumatoid arthritis. Nat Med 3 (1997) 189-195
32. Zwerina J., Redlich K., Schett G., and Smolen J. Pathogenesis of rheumatoid arthritis: targeting cytokines. Ann N Y Acad Sci 1051 (2005) 716-729
33. Szekanecz Z., Kim J., and Koch A. Chemokines. In: Smolen J., and Lipsky P. (Eds). Targeted therapies in rheumatology (2003), Martin Dunitz, London 345-357
34. Haringman J., Oostendorp R., and Tak P. Targeting cellular adhesion molecules, chemokines and chemokine receptors in rheumatoid arthritis. Expert Opin Emerg Drugs 10 (2005) 299-310
35. Smolen J., and Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov 2 (2003) 473-488
36. Zuany-Amorim C., Hastewell J., and Walker C. Toll-like receptors as potential therapeutic targets for multiple diseases. Nat Rev Drug Discov 1 (2002) 797-807
37. Goldsmith C., Boers M., Bombardier C., and Tugwell P. Criteria for clinically important changes in outcomes: development, scoring and evaluation of rheumatoid arthritis patients and trial profiles. J Rheumatol 20 (1993) 561-565
38. van der Heijde D., van't Hof M., van Riel P., van Leeuwen M., van Rijswijk M., and van de Putte L. Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. Ann Rheum Dis 51 (1992) 177-181
39. Aletaha D., and Smolen J. The definition and measurement of disease modification in inflammatory rheumatic diseases. Rheum Dis Clin North Am 32 (2006) 9-44
40. Felson D., Anderson J., Boers M., et al. American College of Rheumatology: preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38 (1995) 727-735
41. van Gestel A., Anderson J., van Riel P., et al. ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. J Rheumatol 26 (1999) 705-711
42. Smolen J., Breedveld F., Schiff M., et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology 42 (2003) 244-257
43. Aletaha D., Nell V., Stamm T., et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 7 (2005) R796-R806
44. Aletaha D., Ward M., Machold K., Nell V., Stamm T., and Smolen J. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum 52 (2005) 2625-2636
45. Makinen H., Kautiainen H., Hannonen P., and Sokka T. Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis?. Ann Rheum Dis 64 (2005) 1410-1413
46. van der Heijde D., Klareskog L., Boers M., et al. Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results. Ann Rheum Dis 64 (2005) 1582-1587
47. Mierau M., Schoels M., Gonda G., Fuchs J., Aletaha D., and Smolen J. Assessing remission in clinical practice. Rheumatology (Oxford) 46 (2007) 975-979
48. Smolen J., and Aletaha D. What should be our treatment goal in rheumatoid arthritis today?. Clin Exp Rheumatol 24 6 suppl 43 (2006) S007-S013
49. Sharp J., Lidsky M., Collins L., and Moreland J. Methods of scoring the progression of radiologic changes in rheumatoid arthritis: correlation of radiologic, clinical and laboratory abnormalities. Arthritis Rheum 14 (1971) 706-720
50. Sharp J., Young D., Bluhm G., et al. How many joints in the hands and wrists should be included in a score of radiologic abnormalities used to assess rheumatoid arthritis?. Arthritis Rheum 28 (1985) 1326-1335
51. Genant H. Methods of assessing radiographic change in rheumatoid arthritis. Am J Med 75 (1983) 35-47
52. van der Heijde D., van Riel P., Nuver-Zwart I., Gribnau F., and van de Putte L. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1 (1989) 1036-1038
53. Strand V., and Sharp J. Radiographic data from recent randomized controlled trials in rheumatoid arthritis: what have we learned?. Arthritis Rheum 48 (2003) 21-34
54. Aletaha D., Smolen J., and Ward M. Measuring function in rheumatoid arthritis: identifying reversible and irreversible components. Arthritis Rheum 54 (2006) 2784-2792
55. Smolen J., and Aletaha D. Patients with rheumatoid arthritis in clinical care. Ann Rheum Dis 63 (2004) 221-225
56. Fries J., Spitz P., Kraines R., and Holman H. Measurement of patient outcome in arthritis. Arthritis Rheum 23 (1980) 137-145
57. Ware Jr. J., and Sherbourne C. The MOS 36-item short-form health survey (SF-36): I-conceptual framework and item selection. Med Care 30 (1992) 473-483
58. Pincus T., Yazici Y., Sokka T., Aletaha D., and Smolen J. Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol 21 5 suppl 31 (2003) S179-S185
59. Weinblatt M. Rheumatoid arthritis in 2003: where are we now with treatment?. Ann Rheum Dis 62 suppl 2 (2003) ii94-ii96
60. Weinblatt M. Efficacy of methotrexate in rheumatoid arthritis. Br J Rheumatol 34 suppl 2 (1995) 43-48
61. Aletaha D., and Smolen J. Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis: an observational study. J Rheumatol 29 (2002) 1631-1638
62. Klareskog L., van der Heijde D., de Jager J., et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363 (2004) 675-681
63. St Clair E., van der Heijde D., Smolen J., et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized controlled trial. Arthritis Rheum 50 (2004) 3432-3443
64. Breedveld F., Weisman M., Kavanaugh A., et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54 (2006) 26-37
65. Lipsky P., van der Heijde D., St Clair E., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 343 (2000) 1594-1602
66. Keystone E., Kavanaugh A., Sharp J., et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 50 (2004) 1400-1411
67. Weinblatt M., Kremer J., Bankhurst A., et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340 (1999) 253-259
68. Brown A., Conaghan P., Karim Z., et al. The relevance of sub-clinical synovitis in the longitudinal assessment of RA: MRI-detected inflammation predicts structural progression in patients in apparent clinical remission. Arthritis Rheum 54 suppl (2006) 4034
69. Kay J., Matteson E., Dasgubpta B., et al. One-year results of golimumab compared with placebo in patients with active RA despite treatment with methotrexate: a phase II, randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 54 suppl (2006) S833 (abstr)
70. Choy E., Hazleman B., Smith M., et al. Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology 41 (2002) 1133-1137
71. Nishimoto N., Hashimoto J., Miyasaka N., et al. Study of Active Controlled Monotherapy Used for Rheumatoid Arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X-Ray Reader-Blinded Randomized Controlled Trial of Tocilizumab. Ann Rheum Dis (2007). published online May 7. DOI:10.1136/ard.2006.068064
72. Cohen S., Emery P., Greenwald M., et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a mulitcenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54 (2006) 2793-2806
73. Kremer J., Genant H., Moreland L., et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 144 (2006) 865-876
74. Smolen J., Han C., Bala M., et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 52 (2005) 1020-1030
75. Smolen J., van der Heijde D., St Clair E., et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 54 (2006) 702-710
76. Goekoop-Ruiterman Y., de Vries-Bouwstra J., Allaart C., et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 52 (2005) 3381-3390
77. Smolen J., Sokka T., Pincus T., and Breedveld F. A proposed treatment algorithm for rheumatoid arthritis: aggressive therapy, methotrexate, and quantitative measures. Clin Exp Rheumatol 21 suppl 21 (2003) S209-S210
78. Grigor C., Capell H., Stirling A., et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364 (2004) 263-269
79. Stashenko P., Nadler L., Hardy R., and Schlossman S. Characterization of a human B lymphocyte-specific antigen. J Immunol 125 (1980) 1678-1685
80. Valentine M., Meier K., Rossie S., and Clark E. Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes: regulation by protein kinase C. J Biol Chem 264 (1989) 11282-11287
81. Einfeld D., Brown J., Valentine M., Clark E., and Ledbetter J. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J 7 (1988) 711-717
82. Browning J. B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nat Rev Drug Discov 5 (2006) 564-576
83. Reff M., Carner K., Chambers K., et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83 (1994) 435-445
84. Maloney D., Smith B., and Rose A. Rituximab: mechanism of action and resistance. Semin Oncol 29 suppl 2 (2002) 2-9
85. Clynes R., Towers T., Presta L., and Ravetch J. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6 (2000) 443-446
86. Johnson P., and Glennie M. Rituximab: mechanisms and applications. Br J Cancer 85 (2001) 1619-1623
87. Czuczman M. Combination chemotherapy and rituximab. Anticancer Drugs 12 suppl 2 (2001) S15-S19
88. Edwards J., Szczepanski L., Szechinski J., et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350 (2004) 2572-2581
89. Emery P., Fleischmann R., Filipowicz-Sosnowska A., et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 54 (2006) 1390-1400
90. Edwards J., and Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 40 (2001) 205-211
91. Kremer J., Westhovens R., Leon M., et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 349 (2003) 1907-1915
92. Genovese M., Becker J., Schiff M., et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. N Engl J Med 353 (2005) 1114-1123
93. Keystone E., Emery P., Peterfy C., et al. Prevention of joint structural damage at 1 year with rituximab in rheumatoid arthritis patients with an inadequate response to one or more TNF inhibitors (REFLEX study). Ann Rheum Dis 65 suppl II (2006) 58
94. Leandro M., Cambridge G., Ehrenstein M., and Edwards J. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 54 (2006) 613-620
95. Linsley P., Brady W., Urnes M., Grosmaire L., Damle N., and Ledbetter J. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 174 (1991) 561-569
96. Collins A., Brodie D., Gilbert R., et al. The interaction properties of costimulatory molecules revisited. Immunity 17 (2002) 201-210
97. Salomon B., and Bluestone J. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 19 (2001) 225-252
98. Webb L., Walmsley M., and Feldmann M. Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: requirement for both B7-1 and B7-2. Eur J Immunol 26 (1996) 2320-2328
99. Moreland L., Alten R., Van den Bosch F., et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 46 (2002) 1470-1479
100. Kremer J., Dougados M., Emery P., et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52 (2005) 2263-2271
101. Emery P., Kosinski M., Li T., et al. Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life. J Rheumatol 33 (2006) 681-689
102. Schiff M., Keiserman M., Codding C., et al. The efficacy and safety of abatacept or infliximab in RA patients with an inadequate response to MTX: results from a 1-year double-blind, randomized, placebo-controlled trial. Arthritis Rheum 54 suppl (2006) 4117 (abstr)
103. Weinblatt M., Schiff M., Goldman A., et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann Rheum Dis 66 (2007) 228-234
104. Weinblatt M., Combe B., Covucci A., Aranda R., Becker J., and Keystone E. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum 54 (2006) 2807-2816
105. Schiff M., Bulpitt K., Weaver A., et al. Safety of combination therapy of anakinra with etanercept in patients with rheumatoid arthritis. Arthritis Rheum 44 suppl (2001) S79 (abstr)
106. Wendling D., Racadot E., and Wijdenes J. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J Rheumatol 20 (1993) 259-262
107. Murakami M., Hibi M., Nakagawa N., et al. IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase. Science 260 (1993) 1808-1810
108. Kotake S., Sato K., Kim K., et al. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res 11 (1996) 88-95
109. Mihara M., Kotoh M., Nishimoto N., et al. Humanized antibody to human interleukin-6 receptor inhibits the development of collagen arthritis in cynomolgus monkeys. Clin Immunol 98 (2001) 319-326
110. Takagi N., Mihara M., Moriya Y., et al. Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. Arthritis Rheum 41 (1998) 2117-2121
111. Medical News Today. Actemra-world's first drug for Castleman's disease-launched in Japan. http://www.medicalnewstoday.com/medicalnews.php?newsid=26049 (accessed March 6, 2007)
112. Nishimoto N., Kanakura Y., Aozasa K., et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 106 (2005) 2627-2632
113. Choy E., Isenberg D., Garrood T., et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum 46 (2002) 3143-3150
114. Nishimoto N., Yoshizaki K., Maeda K., et al. Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis: phase I/II clinical study. J Rheumatol 30 (2003) 1426-1435
115. Nishimoto N., Yoshizaki K., Miyasaka N., et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 50 (2004) 1761-1769
116. De Rycke L., Verhelst X., Kruithof E., et al. Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis. Ann Rheum Dis 64 (2005) 299-302
117. Maini R., Taylor P., Szechinski J., et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 54 (2006) 2817-2829
118. Maini R., Breedveld F., Kalden J., et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41 (1998) 1552-1563
119. Genentech. Full prescribing information: rituxan (rituximab). http://www.gene.com/gene/products/information/oncology/rituxan/insert.jsp (accessed April 27, 2006)
120. US Food and Drug Administration. Rituxan (rituximab) label information. http://www.fda.gov/cder/foi/label/2007/103705s5247Lbl.pdf (accessed April 15, 2007)
121. European Medicines Agency. Authorised medicines for human use: mabthera. http://www.emea.eu.int/humandocs/Humans/EPAR/mabthera/mabthera.htm (accessed March 6, 2007)
122. FDA. MedWatch: 2006 safety information alerts: rituxan (rituximab). http://www.fda.gov/medwatch/safety/2006/safety06.htm#rituxan (accessed March 6, 2007)
123. Itoh K., Kano T., Nagashio C., Mimori A., Kinoshita M., and Sumiya M. Progressive multifocal leukoencephalopathy in patients with systemic lupus erythematosus. Arthritis Rheum 54 (2006) 1020-1022
124. Yousry T., Major E., Ryschkewitsch C., et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 354 (2006) 924-933
125. Berger J. Natalizumab and progressive multifocal leukoencephalopathy. Ann Rheum Dis 65 suppl 3 (2006) iii2-15
126. Roll P., Palanichamy A., Kneitz C., Dorner T., and Tony H. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum 54 (2006) 2377-2386
127. US Food and Drug Administration. Abatacept label information. http://www.fda.gov/cder/foi/label/2007/125118s0016lbl.pdf (accessed April 15, 2007)
128. Baecklund E., Iliadou A., Askling J., et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 54 (2006) 692-701
129. Baslund B., Tvede N., Danneskiold-Samsoe B., et al. Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study. Arthritis Rheum 52 (2005) 2686-2692
130. McInnes I., Liew F., and Gracie J. Interleukin-18: a therapeutic target in rheumatoid arthritis?. Arthritis Res Ther 7 (2005) 38-41
131. Asquith D., and McInnes I. Emerging cytokine targets in rheumatoid arthritis. Curr Opin Rheumatol 19 (2007) 246-251
132. Dinarello C., and Kim S. The biology of human interleukin-32. In: Smolen J., and Lipsky P. (Eds). Contemporary targeted therapies in rheumatology (2007), Martin Dunitz, London (in press)
133. Emery P., and Ponchel F. Inhibiting toll-like receptors in inflammatory disease. Lancet 368 (2006) 821-822
134. Vanags D., Williams B., Johnson B., et al. Therapeutic efficacy and safety of chaperonin 10 in patients with rheumatoid arthritis: a double-blind randomised trial. Lancet 368 (2006) 855-863
135. Barksby H., Milner J., Patterson A., et al. Matrix metalloproteinase 10 promotion of collagenolysis via procollagenase activation: implications for cartilage degradation in arthritis. Arthritis Rheum 54 (2006) 3244-3253
136. Keystone E. Treatments no longer in development for rheumatoid arthritis. Ann Rheum Dis 61 suppl 2 (2002) ii43-ii45
137. Aringer M., Watford W., and O'Shea J. Stats and Jaks. In: Smolen J., and Lipsky P. (Eds). Targeted therapies in rheumatology (2003), Martin Dunitz, London 404-420
138. Karin M., and Lin A. NF-κB at the crossroads of life and death. Nat Immunol 3 (2002) 221-227
139. Kremer J., Bloom B., Breedveld F., et al. A randomized, double-blind, placebo-controlled trial of 3 dose levels of CP-690,550 versus placebo in the treatment of active rheumatoid arthritis. Arthritis Rheum 54 (2006) 4116 (abstr)
140. Cohen S., Hurd E., Cush J., et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46 (2002) 614-624
141. McClung M., Lewiecki E., Cohen S., et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354 (2006) 821-831
142. Cohen S., Valen P., Ritchlin C., et al. RANKL inhibition with denosumab reduces progression of bone erosions in patients with rheumatoid arthritis: month 6 MRI results. Arthritis Rheum 54 (2006) S831
143. Redlich K., Hayer S., Maier A., et al. Tumor necrosis factor α-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum 46 (2002) 785-792
144. Jarrett S., Conaghan P., Sloan V., et al. Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis. Arthritis Rheum 54 (2006) 1410-1414
145. Grey A., and Reid I. Emerging and potential therapies for osteoporosis. Expert Opin Investig Drugs 14 (2005) 265-278
146. Diarra D., Stolina M., Polzer K., et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 13 (2007) 156-163
147. Folkman J. Angiogenesis. In: Smolen J., and Lipsky P. (Eds). Targeted therapies in rheumatology (2003), Martin Dunitz, London 111-131
148. Emery P., and Salmon M. Early rheumatoid arthritis: time to aim for remission?. Ann Rheum Dis 54 (1995) 944-947
149. Quinn M., Conaghan P., O'Connor P., et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 52 (2005) 27-35
150. Furst D., Breedveld F., Kalden J., et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2005. Ann Rheum Dis 65 suppl 3 (2005) iii2-15
151. Smolen J., Keystone E., Emery P., et al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 66 (2007) 143-150
152. van Vollenhoven R., Harju A., Brannemark S., and Klareskog L. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor α blockers can make sense. Ann Rheum Dis 62 (2003) 1195-1198
153. Buch M., Seto Y., Bingham S., et al. C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept. Arthritis Rheum 52 (2005) 42-48
154. Geusens P., Landewe R., Garnero P., et al. The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. Arthritis Rheum 54 (2006) 1772-1777
155. Aletaha D, Funovits J, Keystone EC, Smolen JS. Disease activity in the early course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum (in press).